Facets (new session)
Description
Metadata
Settings
owl:sameAs
Inference Rule:
b3s
b3sifp
dbprdf-label
facets
http://dbpedia.org/resource/inference/rules/dbpedia#
http://dbpedia.org/resource/inference/rules/opencyc#
http://dbpedia.org/resource/inference/rules/umbel#
http://dbpedia.org/resource/inference/rules/yago#
http://dbpedia.org/schema/property_rules#
http://www.ontologyportal.org/inference/rules/SUMO#
http://www.ontologyportal.org/inference/rules/WordNet#
http://www.w3.org/2002/07/owl#
ldp
oplweb
skos-trans
virtrdf-label
None
About:
Amelioration of COVID‐19 related cytokine storm syndrome: Parallels to chimeric antigen receptor‐T cell cytokine release syndrome
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
schema:ScholarlyArticle
, within Data Space :
covidontheweb.inria.fr
associated with source
document(s)
Type:
Academic Article
research paper
schema:ScholarlyArticle
New Facet based on Instances of this Class
Attributes
Values
type
Academic Article
research paper
schema:ScholarlyArticle
isDefinedBy
Covid-on-the-Web dataset
title
Amelioration of COVID‐19 related cytokine storm syndrome: Parallels to chimeric antigen receptor‐T cell cytokine release syndrome
Creator
Hay, Kevin
Chen, Luke
Abdulla, Alym
Biggs, Catherine
Cooper Bmlsc, Jennifer
Hoiland, Ryan
Lee, Agnes
Sekhon, Mypinder
Shojania, Kamran
Stukas Phd, Sophie
Thiara, Sonny
Wellington, Cheryl
source
Medline; PMC
abstract
Coronavirus disease‐2019 (COVID‐19) severity appears to parallel the host immune response, with a subset of patients developing COVID‐19 cytokine storm syndrome (CSS).(1) Serum inflammatory cytokines are elevated in COVID‐19,(2–5) and interleukin (IL)‐6 appears to play a central role in COVID‐19 related CSS.(6–8) Based on the success of IL‐6 receptor blockade for chimeric antigen receptor T‐cell therapy associated cytokine release syndrome (CAR T‐cell CRS), similar strategies using tocilizumab are being investigated in COVID‐19.
has issue date
2020-06-25
(
xsd:dateTime
)
bibo:doi
10.1111/bjh.16961
bibo:pmid
32584416
has license
no-cc
sha1sum (hex)
9f4010a6b7072ccf196c0a415f041fcd2a863b73
schema:url
https://doi.org/10.1111/bjh.16961
resource representing a document's title
Amelioration of COVID‐19 related cytokine storm syndrome: Parallels to chimeric antigen receptor‐T cell cytokine release syndrome
has PubMed Central identifier
PMC7361645
has PubMed identifier
32584416
schema:publication
Br J Haematol
resource representing a document's body
covid:9f4010a6b7072ccf196c0a415f041fcd2a863b73#body_text
is
schema:about
of
named entity 'cytokine release syndrome'
named entity 'receptor'
named entity 'tocilizumab'
named entity 'COVID'
named entity 'cytokine storm syndrome'
named entity 'COVID-19'
named entity 'COVID-19'
named entity '20%'
named entity 'tocilizumab'
named entity 'arterial pressure'
named entity 'IL-6'
named entity 'COVID'
named entity 'CAR T-cell'
named entity 'COVID'
named entity 'case series'
named entity 'IL-10'
named entity 'IL-6 receptor'
named entity 'CSS'
named entity 'IL-6'
named entity 'intravenous'
named entity 'COVID-19'
named entity 'critically ill'
named entity 'COVID-19'
named entity 'norepinephrine'
named entity 'pg/mL'
named entity 'CSS'
named entity 'COVID-19'
named entity 'tocilizumab'
named entity 'ICU'
named entity 'COVID'
named entity 'CAR-T cell'
named entity 'cytokine release syndrome'
named entity 'tocilizumab'
named entity 'inflammatory cytokines'
named entity 'IL-6'
named entity 'IL-6'
named entity 'CAR-T'
named entity 'CRS'
named entity 'tocilizumab'
named entity 'COVID'
named entity 'IL-6 receptor'
named entity 'pg/mL'
named entity 'inflammatory conditions'
named entity 'tocilizumab'
named entity 'T-cell'
named entity 'IL-1β'
named entity 'invasive mechanical ventilation'
named entity 'IL-6'
named entity 'IL-6'
named entity 'critically ill'
named entity 'COVID'
named entity 'CAR-T'
named entity 'case series'
named entity 'immune response'
named entity 'tocilizumab'
named entity 'CRS'
named entity 'CSS'
named entity 'biological plausibility'
named entity 'CRS'
named entity 'COVID'
named entity 'COVID-19'
named entity 'serum'
named entity 'tocilizumab'
named entity 'CSS'
named entity 'IL-6'
named entity 'COVID'
named entity 'inflammatory markers'
named entity 'COVID'
named entity 'reference range'
named entity 'interleukin (IL)-6'
◂◂ First
◂ Prev
Next ▸
Last ▸▸
Page 1 of 2
Go
Faceted Search & Find service v1.13.91 as of Mar 24 2020
Alternative Linked Data Documents:
Sponger
|
ODE
Content Formats:
RDF
ODATA
Microdata
About
OpenLink Virtuoso
version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software